{"id":"W2591022134","doi":"10.1200/jco.2009.27.15_suppl.1033","title":"Safety and efficacy of first-line bevacizumab (B) plus chemotherapy (CT) for locally recurrent or metastatic breast cancer (LR/mBC): Analysis of MO19391 according to CT","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Taxane; Vinorelbine; Metastatic breast cancer; Internal medicine; Docetaxel; Capecitabine; Bevacizumab; Clinical endpoint; Population; Oncology; Trastuzumab; Surgery; Chemotherapy; Gastroenterology; Breast cancer; Cancer; Clinical trial; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001726822,0.0003064265,0.0005799903,0.0004266149,0.0001574796,0.0004276216,0.0004019549,0.0004824649,0.002221923],"category_scores_gemma":[0.00224947,0.0001756906,0.001081563,0.0004732542,0.0003707743,0.0003143331,0.0002369059,0.0006429792,0.0004300997],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008184707,"about_ca_system_score_gemma":0.0004476266,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001107536,"about_ca_topic_score_gemma":0.0009408278,"domain_scores_codex":[0.9991065,0.0004291482,0.00007544937,0.0001534828,0.0001587368,0.0000767094],"domain_scores_gemma":[0.9979815,0.0006141982,0.0008715359,0.0001454985,0.00009520362,0.000292031],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3291828,0.002771731,0.6047041,0.000238163,0.002790072,0.0002257984,0.0001543795,0.00183452,0.01219056,0.0001132904,0.0009871683,0.0448073],"study_design_scores_gemma":[0.01225978,0.04745964,0.9317473,0.00002761656,0.001151908,0.0007215459,0.00004404125,0.002929314,0.002218721,0.0001647527,0.001249936,0.00002543871],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.998404,0.000465979,0.0001384805,0.00003197774,0.000005643255,0.00008246636,0.0004785672,0.000008020392,0.0003850498],"genre_scores_gemma":[0.998698,0.00009819859,0.0001074067,0.00005142655,0.00001181435,0.00004269921,0.0008201987,0.00000488224,0.0001654419],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002221923,"threshold_uncertainty_score":0.009132385,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1253006278999587,"score_gpt":0.5168701766002968,"score_spread":0.3915695487003381,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}